BioMarin Pharmaceutical Inc. (BMRN) has converted a global patent dispute with Ascendis Pharma A/S (ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment for achondroplasia. BioMarin will receive royalties equal to 20% of U.S. Yuviwel net sales, retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil, and South Korea through May 2030. The settlement resolves proceedings before the U.S. International Trade Commission and courts in several countries, eliminating litigation costs and uncertainty.